&lt;p&gt;Association of Silicone Breast Implants, Breast Cancer and Anti-RNA Polymerase III Autoantibodies in Systemic Sclerosis: Case-Based Review&lt;/p&gt;

Angelis, Rossella De; Battista, Jacopo Di; Smerilli, Gianluca; Cipolletta, Edoardo; Carlo, Marco Di; Salaffi, Fausto

doi:10.2147/oarrr.s262428

Cited by 6 publications

(4 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With the increasing use of silicone breast implants, it has been postulated that silicone could also lead to an increase in autoimmunity by creating a chronic inflammatory state and/or functioning as an adjuvant, thus lowering the threshold for the loss of self-tolerance. Separate case studies from Italy confirmed a higher frequency of silicone breast implants [13] and a higher risk for rupture [14] specifically in patients with ARA-positive SSc. Although smoking has been identified as a potential trigger for autoimmunity in general [15], and a risk factor for worse prognosis in patients with SSc [16], ATA were found to be negatively associated with smoking (OR 1.77, 95% CI 1.04–2.99, P = 0.034) [17].…”

Section: Triggers/initiating Eventsmentioning

confidence: 84%

“…Overview of autoantibody development in SSc. Viral infections, silica, and malignancy have recently been studied as potential triggers for autoantibody development [4–8,10–14,18–20,21 ▪ ]. These initiating events lead to a breach of tolerance at the level of DC:T cell interactions, which may be influenced by SSc-associated motifs in the DRB1 peptide-binding groove [26 ▪▪ ,27].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Insights into origins and specificities of autoantibodies in systemic sclerosis

Tiniakou

Crawford

Darrah

2021

Current Opinion in Rheumatology

View full text Add to dashboard Cite

Purpose of reviewAutoantibodies are hallmark findings in systemic sclerosis (SSc), often present prior to disease onset. Clinical diagnosis and prognosis of SSc have long relied on the antitopoisomerase – anticentromere – anti-RNA polymerase antibody trichotomy. However, many more autoantibodies found in SSc are being actively investigated for insights into triggering events, mechanisms of tolerance break, and connections to tissue damage. This review examines recent studies on SSc autoantibodies and the early events that lead to their development.Recent findingsRecent work has elucidated potential connections between human cytomegalovirus infection, silicone breast implants, and malignancy to SSc autoantibody development. At the level of the dendritic cell:T cell interaction, where tolerance is broken, new studies identified shared motifs in the peptide-binding domains of SSc-associated human leukocyte antigen alleles. Immunological analysis of SSc patient B cells has uncovered several anomalies in the regulatory capacities of SSc naïve and memory B cell populations. Expanding efforts to uncover new SSc autoantibodies revealed anti-CXCL4, anticollagen V, and other autoantibodies as potential players in disease pathogenesis.SummaryFurther research into the role of autoantibodies in SSc development may uncover new mechanism-guided therapeutic targets. In addition, a better understanding of autoantibody associations with SSc disease outcomes will improve clinical care.

show abstract

Section: Triggers/initiating Eventsmentioning

confidence: 84%

Section: Introductionmentioning

confidence: 99%

Insights into origins and specificities of autoantibodies in systemic sclerosis

Tiniakou

Crawford

Darrah

2021

Current Opinion in Rheumatology

View full text Add to dashboard Cite

show abstract

“…Several case studies link silicone breast implants with increased incidence of ARA positive scleroderma and silicone breast implant rupture has been implicated in induction of ARA positive SSc [44,45].…”

Section: Antigen Triggersmentioning

confidence: 99%

Scleroderma autoantibodies in guiding monitoring and treatment decisions

Shah

Denton

2022

Current Opinion in Rheumatology

View full text Add to dashboard Cite

Purpose of reviewOne of the key clinical challenges of systemic sclerosis (SSc) is diversity in clinical presentation, organ involvement and disease progression. Antinuclear autoantibodies (ANA) are central to the diagnosis of SSc. ANA specificities associated with distinct clinical patterns of organ and skin involvement. Understanding of the molecular differences and pathogenesis of scleroderma has helped further inform clinical acumen. Here, we provide an update on ANA on clinical profiling, management and future direction of SSc.Recent findingsThere has been further development in delineating clinical patterns in ANA, genetic susceptibility and antigen triggers predisposing to ANA subtypes. Sub-group analysis of recent clinical trials shows differing treatment responses to novel therapeutics.SummaryANA subtyping is likely to be firmly embedded into future classification systems. Beyond informing current management and monitoring of scleroderma patients, ANA subsets have implication on future research and clinical trial design.

show abstract

“…На сегодняшний день индивидуальные принципы скрининга РМЖ у пациенток с ССД не разработаны и, вероятно, соответствуют таковым в общей популяции. Особенно важно в данной ситуации перед назначением МГТ определять анти-RNP III, особенно у пациенток с диффузной формой ССД [65].…”

Section: риск развития рака молочной железы при системной склеродермииunclassified

Pathogenetic rationale for prescribing menopausal hormone therapy for systemic sclerosis

Panevin¹,

Ananieva²

2022

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

Systemic scleroderma (SS) is characterized by dysregulation of the innate and adaptive immune systems, vasculopathy, and generalized fibrosis. As with most autoimmune diseases, women predominate among patients, who get sick 3–14 times more often than men. It is assumed that gender differences and modulation of sex hormones are essential in the pathogenesis of SS. Estrogens are able to influence the immune response, have a vasodilating effect and stimulate the synthesis of collagen in the skin. The development of SS leads to a significant decrease in the quality of life, psychological disorders associated with changes in appearance, as well as the need for lifelong medication with the frequent development of side effects. Age-related estrogen deficiency associated with the onset of menopause is accompanied by a decrease in the quality of life and, in some cases, a change in the clinical manifestations of somatic diseases. This review considers the impact of menopause and menopausal hormone therapy (MHT) on the course and clinical manifestations of systemic scleroderma. It is noted that SS in some cases is accompanied by an early onset of menopause. The use of MHT is not associated with the progression of cutaneous fibrosis, and may also improve the vascular manifestations of SS.

show abstract

<p>Association of Silicone Breast Implants, Breast Cancer and Anti-RNA Polymerase III Autoantibodies in Systemic Sclerosis: Case-Based Review</p>

Cited by 6 publications

References 42 publications

Insights into origins and specificities of autoantibodies in systemic sclerosis

Insights into origins and specificities of autoantibodies in systemic sclerosis

Scleroderma autoantibodies in guiding monitoring and treatment decisions

Pathogenetic rationale for prescribing menopausal hormone therapy for systemic sclerosis

Contact Info

Product

Resources

About